Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 11, Issue 7, 1997, Pages 875-877

  Grocott, Hilary P ^a   Root, Jennifer ^a   Berkowitz, Scott D ^a   DeBruijn, Norbert ^a   Landolfo, Kevin ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cardiopulmonary bypass; Coagulation; Danaparoid sodium; Heparin induced thrombocytopenia; Heparinoid; Org 10172

Indexed keywords

DANAPAROID; HEPARINOID;

AGED; ARTICLE; BLEEDING; CARDIOPULMONARY BYPASS; CASE REPORT; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; HUMAN; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0030729220     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-0770(97)90124-5     Document Type: Article

References (27)

1. Warkentin TE, Kelton J: The platelet life cycle: Quantitative disorders, in Handin R, Lux S, Stossel T (eds): Blood. Principles & Practice of Hematology. Philadelphia, PA, Lippincott, 1995, pp 998-1036
2. Makhoul RG, McCann RL, Austin EH, et al: Management of patients with heparin-associated thrombocytopenia and thrombosis requiring cardiac surgery. Ann Thorac Surg 43:617-621, 1987
3. Cola C, Ansell J: Heparin-induced thrombocytopenia and arterial thrombosis: Alternative therapies. Am Heart J 119:368-374, 1990
4. Doherty DC, Ortel TL, deBruijn N, et al: "Heparin-free" cardiopulmonary bypass: First reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass. Anesthesiology 73:562-565, 1990
5. Rowlings PA, Mansberg R, Evans S, Murray B: The use of a low-molecular-weight heparinoid (Org 10172) for extracorporeal procedures in patients with heparin-dependent thrombocytopenia and thrombosis. Aust NZ J Med 21:52-54, 1991
6. Hirsh J, Levine M: Low molecular weight heparin: Laboratory properties and clinical evaluation. Eur J Surg 571:9-22, 1994 (suppl)
7. Olinger GN, Hussey CV, Olive JA, Malik MI: Cardiopulmonary bypass for patients with previously documented heparin-induced platelet aggregation. J Thorac Cardiovasc Surg 87:673-677, 1984
8. Reiss F, Lower C, Seeling C, et al: Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: Successful for aortic valve replacement in man. J Thorac Cardiovasc Surg 110:1-3, 1995
9. Edmunds LJ: HIT, HITT, and desulfatohirudin. J Thorac Cardiovasc Surg 110:1-3, 1995
10. Bernabei A, Rao A, Niewiarowski S, et al: Recombinant desulfatohirudin as a substitute for heparin during cardiopulmonary bypass. J Thorac Cardiovasc Surg 108:381-382, 1994
11. Zulys V, Teasdale S, Michel E, et al: Ancrod (Arvin) as an alternative to heparin anticoagulation for cardiopulmonary bypass. Anesthesiology 71:870-877, 1989
12. Henny C, ten Cate H, ten Cate J, et al: A randomized blind study comparing standard heparin and a new low-molecular-weight heparinoid in cardiopulmonary bypass surgery. J Lab Clin Med 106:187-196, 1985
13. Cannell P, Herrmann R, Marshall L: Heparinoid and cardiopulmonary bypass. Aust NZ J Med 21:141, 1991 (suppl 1)
14. Danhof M, de Boer A, Magnani H, Stiekema J: Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Hemostasis 22:73-84, 1992
15. Makhoul RG, Greenberg CS, McCann RL: Heparin-associated thrombocytopenia and thrombosis: A serious clinical problem and potential solution. J Vasc Surg 4:522-528, 1986
16. Chong BH, Grace CS, Rozenberg MC: Heparin-induced thrombocytopenia: Effect of heparin platelet antibody on platelets. Brit J Hematol 49:531-540, 1981
17. Warkentin T, Levine M, Hirsh J, et al: Heparin-induced thrombocytopenia in patients with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332:1330-1335, 1995
18. Aster R: Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 332:1374-1376, 1995
19. Keeling D, Richards E, Baglin T: Platelet aggregation in response to four low-molecular-weight heparins and the heparinoid Org 10172 in patients with heparin-induced thrombocytopenia. Brit J Hemat 86:425-426, 1994
20. Warkentin T, Kelton J: A fourteen year study of heparin-induced thrombocytopenia. Am J Med 101:502-507, 1996
21. Ramakrishna R, Manoharan A, Kwan Y, Kyle P: Heparin-induced thrombocytopenia: Cross-reactivity between standard heparin, low-molecular-weight heparin, dalteparin (fragmin) and heparinoid, danaparoid (orgaran). Brit J Hemat 91:736-738, 1995
22. Addonizio VP, Fisher CA, Kappa JR, Ellison N: Prevention of heparin-induced thrombocytopenia during open heart surgery with iloprost (ZK36374). Surgery 102:796-807, 1987
23. Ofosu F: Anticoagulant mechanisms of orgaran (Org 10172) and its fraction with high affinity to antithrombin III (Org 10849). Hemostasis 22:66-72, 1992
24. Meuleman D: Orgaran (Org 10172): Its pharmacologic profile in experimental models. Hemostasis 22:58-65, 1992
25. Magnani H: Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with orgaran (Org 10172). Thromb Hemostas 70:554-561, 1993
26. Chong B, Magnani H: Orgaran in heparin-induced thrombocytopenia. Hemostasis 22:85-91, 1992
27. Ortel T, Gockerman J, Califf R, et al: Parenteral anticoagulation with the heparinoid lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. Thromb Hemostas 67:292-296, 1992